RhumbLine Advisers’s Freeline Therapeutics Holdings plc American Depositary Shares FRLN Stock Holding History

RhumbLine Advisers’s Portfolio FRLN Stock Details FRLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-155	Closed	-$985	–	4292
2023 Q4	$985	Buy	155 +40	+35%	+$214	﹤0.01%	4156
2023 Q3	$487	Buy	+115	New	+$455	﹤0.01%	4233

RhumbLine Advisers's FRLN Position: Q1 2024 in Review

RhumbLine Advisers sold out of Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) in Q1 2024, closing a stake of 155 shares — an estimated $985 sold.

RhumbLine Advisers first reported a position in FRLN in Q3 2023 and held it in 2 quarters. The position peaked at $985 in Q4 2023. 0 funds tracked by Wall St. Rank hold FRLN as of Q1 2024.

RhumbLine Advisers reported no remaining Freeline Therapeutics Holdings plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
RhumbLine Advisers sold 155 Freeline Therapeutics Holdings plc American Depositary Shares shares in Q1 2024, an estimated $985.
RhumbLine Advisers first reported a position in Freeline Therapeutics Holdings plc American Depositary Shares in Q3 2023 and held it in 2 quarters.
RhumbLine Advisers's Freeline Therapeutics Holdings plc American Depositary Shares position peaked at $985 in Q4 2023.
0 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings plc American Depositary Shares as of Q1 2024.

Based on RhumbLine Advisers's 13F filing for Q1 2024, filed 9 May 2024.